| Literature DB >> 12808885 |
Anna C Calkin1, Merlin C Thomas, Mark E Cooper.
Abstract
MK-767 (KRP-297, L-410198) is a peroxisome proliferator-activated receptor (PPAR) alpha and PPAR gamma agonist under development by Banyu, Kyorin and Merck for the potential treatment of diabetes. The compound is currently undergoing phase III trials in the US and phase I trials in Japan.Entities:
Mesh：
Substances：
Year: 2003 PMID： 12808885
Source DB: PubMed Journal: Curr Opin Investig Drugs ISSN： 1472-4472